Shares of Firefly Neuroscience Inc. (AIFF) climbed 34.87% to $1.6050 after the company announced a strategic partnership with NeuroSigma. The agreement expands access to NeuroSigma's Monarch eTNS System through Firefly's nationwide clinician network, combining brain assessment technology with a non-drug treatment option for eligible children with ADHD. The collaboration targets improved personalized ADHD care through the companies' advanced solutions.

Partnership Extends Monarch Therapy Through Firefly's Clinician Network

Under the arrangement, Firefly will introduce the Monarch eTNS System to clinicians using its Evoke platform, targeting psychiatry, neurology, and behavioral health practices across the United States. NeuroSigma will support the rollout with training, prescribing support, and product fulfillment services.

The Monarch eTNS System has received clearance from the U.S. Food and Drug Administration for pediatric ADHD treatment. The device offers a non-medication approach for children between seven and twelve years old, delivering mild external trigeminal nerve stimulation through a forehead patch worn during sleep.

Firefly's Evoke platform uses quantitative EEG and ERP testing supported by advanced analytics. The system analyzes brain activity through a database containing more than 200,000 EEG and ERP scans, giving clinicians objective information about brain function and enabling them to track patient changes over time. Pairing that assessment capability with an FDA-cleared, non-medication therapy gives participating practices a direct route from objective brain-function measurement to a treatment option — the kind of combined workflow the partnership is designed to support.

Recent Company Developments

The partnership follows Firefly's continued development of neuroscience solutions focused on personalized care. In March 2026, the company announced EEG and ERP biomarker discoveries linked to ADHD presentations, findings that may support future research into treatment selection and patient monitoring.

NeuroSigma expanded availability of its second-generation Monarch device in July 2026, broadening the therapy's reach, and introduced additional payment options in September to support family access. That expansion followed a waitlist exceeding 1,500 patients, caregivers, and healthcare providers. Those parallel developments — new biomarker findings on the assessment side and device and payment expansion on the treatment side — preceded the partnership.

About the Companies

Firefly Neuroscience develops technology that helps clinicians understand brain activity patterns. Its Evoke platform helps identify differences in neurological function across various conditions, and the company continues building partnerships that connect healthcare providers with new treatment options. Operating in the precision neuroscience sector through its Evoke platform and research programs, Firefly focuses on using brain data to improve clinical decision-making processes.

NeuroSigma develops bioelectronic medical devices for neurological and psychiatric conditions, including the Monarch eTNS System at the center of the new partnership.

Market Reaction

The AIFF stock rally reflected market attention following the announcement of the healthcare collaboration. By combining their platforms, Firefly and NeuroSigma aim to improve access to ADHD care solutions, supporting clinicians with both assessment tools and alternative treatment pathways. The partnership creates a wider channel for Monarch eTNS adoption among healthcare providers and strengthens Firefly's position in the growing digital neuroscience market.

Going forward, the pace at which the Monarch eTNS System reaches psychiatry, neurology, and behavioral health practices through Firefly's network — and whether the March 2026 biomarker findings feed into the treatment-selection research the company has flagged — are among the developments that will show how the collaboration is taking shape. The companies will continue supporting clinician education and patient access through the collaboration.

Source: Blockonomi